Source: Annual Congress 2013 –Pulmonary circulation: treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Mayer, A. M. D'Armini, H. A. Ghofrani, E. Grünig, P. Jansa, N. H. Kim, G. Simonneau, A. Torbicki, C. Wang, M. R. Wilkins, N. Davie, A. Fritsch, M. M. Hoeper (Bad Nauheim, Giessen, Heidelberg, Wuppertal, Hannover, Germany; Pavia, Italy; Prague, Czech Republic; San Diego, United States Of America; Le Kremlin-Bicêtre, France; Warsaw, Poland; Beijing, China; London, United Kingdom). Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study. Eur Respir J 2013; 42: Suppl. 57, 1781

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Longterm survival of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 263-271 Year: 2015 Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Long-term outcomes of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007 Hemodynamic profiles in patients with chronic thromboembolic disease before and after pulmonary endarterectomy Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Pre-operative anaemia does not influence clinical outcome in patients undergoing pulmonary endarterectomy (PEA) Source: International Congress 2016 – Special issues in thoracic surgery Year: 2016 Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Chronic thrombo-embolic pulmonary hypertension: Long-term outcomes in operated and non-operated patients Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016